Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD in healthy volunteers and MAD in Parkinson's disease patients for LY3962681
NL-OMON59725Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2026
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing LY3962681 with Placebo (2 arms). Started Sep 2026; status: recruiting.
02
Drugs
LY3962681
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON59725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59725.